Navigation Links
NeurogesX Provides U.S. Regulatory Update for Qutenza(TM)
Date:6/10/2009

approval for Qutenza; any regulatory approvals which are received may be limited to certain indications; NeurogesX' product candidates may have unexpected adverse side effects or inadequate therapeutic efficacy; and other difficulties or delays in, clinical development of, and obtaining regulatory approval for NeurogesX' product candidates. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

    NeurogesX, Inc.             The Ruth Group
    Stephen Ghiglieri           Sara Pellegrino (investors)
    Chief Financial Officer     (646) 536-7002
    (650) 358-3310              spellegrino@theruthgroup.com

                                Jason Rando (media)/Janine McCargo
                                (646) 536-7025/7033
                                jrando@theruthgroup.com
                                jmccargo@theruthgroup.com



'/>"/>
SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. NeurogesX Appoints New Director to the Board
3. NeurogesX to Present at UBS 2007 Global Life Sciences Conference
4. NeurogesX Expands Senior Management Team
5. NeurogesX to Present at CIBC World Markets 18th Annual Healthcare Conference and Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
6. NeurogesX to Present at Lazard Capital Markets Healthcare Conference
7. NeurogesX, Inc. Announces $25 Million Private Placement
8. NeurogesX Closes $25 Million Private Placement
9. NeurogesX to Present at the 10th Annual BIO CEO & Investor Conference
10. NeurogesX to Present at Roth 2008 OC Growth Stock Conference
11. NeurogesX to Report Fourth Quarter and Year-End 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... October 02, 2014 Freeslate, ... research solutions for biopharmaceutical development, today announced highlights ... 24, 2014 at GlaxoSmithKline (GSK) in Ware, UK. ... of best practices in high throughput research and ... leaders gathered together to discuss the challenges and ...
(Date:10/2/2014)... The National Institutes of Health ... grant today to develop an electrode array system ... the brain works through unprecedented resolution and scale. ... efforts to support President Obama's BRAIN (Brain Research ... effort to revolutionize our understanding of the human ...
(Date:10/2/2014)... , Oct. 2, 2014  NKT Therapeutics ... Administration has granted Fast Track designation to NKTT120, ... treatment of sickle cell disease.  NKTT120 is a ... a regulatory T cell that has been demonstrated ... in preclinical models of sickle cell disease.  Fast ...
(Date:10/1/2014)... 01, 2014 METTLER TOLEDO’s newly improved ... precision balances as well as a dual range ... performance, the new SmartPan™ weighing pan delivers results up ... On all balances, ergonomic design details mean users no ... working for long periods in front of the balance. ...
Breaking Biology Technology:Freeslate European Summit Highlights Best Practices in High Throughput Research and Data Management 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 2NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 3NIH taps Lawrence Livermore to Develop Sophisticated Electrode Array System to Monitor Brain Activity 4FDA Grants Fast Track Designation to NKT Therapeutics' NKTT120 for the Treatment of Sickle Cell Disease 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 2METTLER TOLEDO’s XS Balance Line Delivers Performance and Ergonomics To Safeguard Health in the Workplace 3
... Reportlinker.com announces that a new market research ... Orthopedic Biomaterials, The World Market ... products, which can be organic or synthetic in ... fracture to facilitate healing or to compensate for ...
... 3, 2011 EntreMed, Inc. (Nasdaq: ENMD ... treatment of cancer today announced the presentation of clinical ... platinum-resistant ovarian cancer patients.   The data were presented ... A. Matulonis, medical director of gynecologic oncology at Dana-Farber ...
... 3, 2011 Asmacure Ltee, a clinical-stage ... agonists for the treatment of asthma and other inflammatory ... as chief executive officer.  With a solid foundation established ... it progresses its lead compound, a potential new treatment ...
Cached Biology Technology:Reportlinker Adds Orthopedic Biomaterials, The World Market 2Reportlinker Adds Orthopedic Biomaterials, The World Market 3Reportlinker Adds Orthopedic Biomaterials, The World Market 4EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 2EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 3EntreMed's ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients 4Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 2Asmacure Ltee Appoints Pharmaceutical and Biotechnology Industry Veteran Martin Driscoll as CEO 3
(Date:9/30/2014)... on Earth, but when the climate changes and temperatures ... The amount of time needed to adjust to new ... in the future, reveals a new study from researchers ... journal Proceedings of the Royal Society B . ... of greenhouse gases in the atmosphere. The greenhouse effect ...
(Date:9/30/2014)... in Munich report that a new class of ... chemotherapeutic drugs. They have also pinpointed the relevant ... anti-tumor agents. , Researchers led by LMU,s ... the Technische Universitt Mnchen have identified a class ... in the fight against malignant tumors. The compound ...
(Date:9/30/2014)... Sept. 30, 2014  Spectra Automation, a ... the biotech and power generation industries, announced ... Bioprocess Manager, an easy-to-use and cost-effective data ... bioprocess development laboratories. Most ... and analyzer systems. Accessing and consolidating data ...
Breaking Biology News(10 mins):Shape up quickly -- applies to fish, too! 2Cancer therapy: Driving cancer cells to suicide 2Spectra Automation Introduces RECONN Bioprocess Manager 2
... criminals, requires evidence and witnesses; but on the scale ... easier said than done. A team of ... Arizona State University may soon change that. Under a ... a new way to close the gaps in the ...
... Sarasota FL., December 17, 2007 Researchers at ... of the EASE (Exhale Airway Stents for Emphysema) Trial, ... treatment that may offer a significant new, minimally-invasive option ... focuses on a procedure called airway bypass that involves ...
... latest American Chemical Society (ACS) News Service Weekly PressPac with ... News.,Please credit the individual journal or the American Chemical Society ... FOR IMMEDIATE USE EXCEPT ARTICLE #5, which is embargoed for ... ARTICLE #1 FOR IMMEDIATE RELEASE A faster, ...
Cached Biology News:ASU researchers use NASA satellites to improve pollution modeling 2Researchers at Sarasota Memorial Health Care System to study airway bypass treatment for emphysema 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 2American Chemical Society's Weekly PressPac -- Dec. 12, 2007 3American Chemical Society's Weekly PressPac -- Dec. 12, 2007 4American Chemical Society's Weekly PressPac -- Dec. 12, 2007 5American Chemical Society's Weekly PressPac -- Dec. 12, 2007 6American Chemical Society's Weekly PressPac -- Dec. 12, 2007 7American Chemical Society's Weekly PressPac -- Dec. 12, 2007 8American Chemical Society's Weekly PressPac -- Dec. 12, 2007 9American Chemical Society's Weekly PressPac -- Dec. 12, 2007 10
For demonstration of Helicobacter pylori...
... efficient interfacing with mass spectrometry. Improved ... demands for benefits like these have ... routine applications. Standard HPLC systems, however, ... to operate with smaller bore columns ...
... is used in conjunction with your existing apoptosis ... apoptosis according to your existing procedure (also reserve ... control). Once you have induced apoptosis in your ... population and incubate the cells for an additional ...
Kit Components: Anti-Acetylated Histone H3 Salmon Sperm DNA/Protein A Agarose All necessary buffers. ...
Biology Products: